Introduction {#s1}
============

Crohn's disease (CD) and ulcerative colitis (UC) are classified as chronic, idiopathic inflammatory bowel diseases (IBD) [@pone.0099807-VanAssche1], [@pone.0099807-Mowat1]. Familial aggregation, high concordance in twins and a higher prevalence of the disease in a certain ethnic population imply a strong genetic influence on the risk of disease development [@pone.0099807-Freeman1], [@pone.0099807-Brant1]. Identifying the genetic loci or rare detrimental mutations in different populations or families with the disease will help elucidate the pathogenesis of these complex traits and facilitate the development of more targeted therapy.

It is now widely recognized that common variants shown in GWAS can explain only relatively modest proportions of risk for diseases. Numerous functional and deleterious variants in the population are at frequencies of 0.5 to 5% that are too low to be detected by GWAS [@pone.0099807-Majewski1], [@pone.0099807-Teer1]. As predisposing variants will present at a much higher frequency in the affected relatives of an index case, family studies may facilitate the detection of the 'missing heritability' not identified by GWAS [@pone.0099807-Manolio1]. Exome sequencing, which is a technique that focuses on the protein-coding portion of the genome, is not limited by the detailed and complete pedigree data that are necessary for classical linkage analysis and can be performed on only a few patients for the detection of causal mutations [@pone.0099807-Nazarian1], [@pone.0099807-Gilissen1].

Researchers have successfully identified a causal hemizygous mutation in the XIAP gene [@pone.0099807-Worthey1] and novel compound heterozygous mutations in interleukin-10 receptor 1 (IL-10R1) [@pone.0099807-Mao1], using exome sequencing in children presenting with very early-onset and intractable IBD. The sequencing of eight pediatric IBD patients' exomes revealed various profiles of specific variants with a limited number in each case [@pone.0099807-Christodoulou1].

Numerous candidate genes for Western IBD patients have been shown, but causality for specific variants in Chinese IBD patients is largely absent. In this study, we applied whole exome sequencing to 4 individuals belonging to a same family (Family A) to discover novel deleterious genetic variants associated with IBD and then validated these findings in other 10 family members of Family A, 401 healthy controls (HC), 278 subjects with sporadic CD, 123 subjects with UC, a pair of monozygotic twins and another Han Chinese CD family (Family B).

Materials and Methods {#s2}
=====================

Patients and Controls {#s2a}
---------------------

The familial patients included in this study were selected from the Hubei Clinical Center & Key Lab of Intestinal & Colorectal Diseases. Written informed consent was obtained from all subjects and the next of kin on behalf of the children enrolled in the study. This study was approved by the ethics committee of the Zhongnan Hospital of Wuhan University as part of the human subjects' protocol to study the genetics of IBD in humans. The CD patients and HC were all unrelated subjects of Chinese descent and born to non-consanguineous parents. The ancestry of the patients and control individuals was assessed by self-report and appearance. Phenotypic data were acquired from a review of medical records, phone interviews and photographs. A combination of symptom assessment, laboratory and radiological examinations and endoscopy with histology was applied to make the diagnosis.

For whole exome sequencing, we selected a Han Chinese family (Family A) including a daughter and a father both affected with CD from Hubei province. In this family, the father is the proband, the proband's unaffected mother and wife were taken as exome sequencing controls. The father, who was diagnosed with CD at the age of 31 years in 1999 with terminal ileitis and proctitis, was treated with oral prednisolone and aminosalicylic acid (5-ASA). Small intestine computed tomography enterography (CTE) showed a thickened ileum wall in 2012.

The affected daughter developed CD at the age of 16 years in 2012, with high fever, diarrhea, oral ulcers and an anal fistula. Endoscopy showed upper digestive tract ulcers, aphthous ulcers at the ileocecal junction and colitis involving the rectum, sigmoid colon, descending colon and transverse colon. A biopsy showed non-specific granulomatous inflammation and staining was negative for acid-fast bacilli. She was finally diagnosed with CD and was treated with an intravenous injection of corticosteroids, 5-ASA, immunosuppressants and infliximab for severe refractory disease. She is now in remission with azathioprine and 5-ASA (the supporting data are provided in [Fig. 1](#pone-0099807-g001){ref-type="fig"}).

![Clinical characteristics of two patients in Chinese CD family A.\
The index patient in the family, the father (Panels A to D) had evidence of mucous membrane granulation, polypoid proliferation and hyperemia in his colonoscopy, as shown in Panels A and B. Panel C shows the patient's pathological findings of chronic intestinal inflammation. Panel D shows the thickening of the ileum wall by small intestine computed tomography enterography (CTE). The daughter in the family is another Patient (Panels E to H). Panel E shows her anal fistula at disease onset. Endoscopy showed intestinal poly-ulcers in Panel F. A biopsy showed non-specific granulomatous inflammation, as shown in Panel G, and the higher magnification of the pathology shown in Panel H reveals negative acid-fast staining granulomas. All of the images were collected in March 2012 in Zhongnan Hospital of Wuhan University.](pone.0099807.g001){#pone-0099807-g001}

An additional 10 healthy members' blood DNA samples from family A were also taken as Sanger sequencing controls to validate the co-segregation of the mutations in the CD family.

In addition, 278 sporadic CD and 123 sporadic UC patients were enrolled from the Inflammatory Bowel Disease Center of Zhongnan Hospital of Wuhan University (131 CD, 76 UC), Renji Hospital of Shanghai Jiaotong University School of Medicine (40 CD) and the Institute of Digestive Disease of The Chinese University of Hong Kong (107 CD, 47 UC) from January 2001 to December 2012; 401 HC were from Wuhan, China ([Table 1](#pone-0099807-t001){ref-type="table"}).

10.1371/journal.pone.0099807.t001

###### Characteristics of 401 sporadic inflammatory bowel disease (*IBD*) patients and 401 healthy controls.

![](pone.0099807.t001){#pone-0099807-t001-1}

  Index                    CD 278        UC 123          HC
  --------------------- ------------- ------------- -------------
  Male (n = )                176           72            239
  Female (n = )              102           51            162
  Average age (years)    32.25±13.38   35.40±10.63   36.42±12.42

Moreover, we collected 25 young and intractable CD cases ([Table 2](#pone-0099807-t002){ref-type="table"}), including a pair of monozygotic twins (Patient ID in [Table 2:](#pone-0099807-t002){ref-type="table"} 24 and 25) and 23 cases selected from 131 sporadic CD patients of Hubei province. Another CD family (family B) was also from Wuhan city.

10.1371/journal.pone.0099807.t002

###### Data of 25 young and intractable CD patients.

![](pone.0099807.t002){#pone-0099807-t002-2}

  PatientID    Age atdiagnosis(year)    Sex               Diseaselocation             Treatment                          
  ----------- ----------------------- -------- ------------------------------------- ----------- ----- ----- ----- ----- -----
  1                     25             Female             Terminal ileum                 NO       YES   NO    NO    NO    YES
  2                     15              Male              Terminal ileum                 NO       YES   YES   NO    YES   NO
  3                     24              Male              Terminal ileum                 NO       YES   NO    YES   NO    NO
  4                     34              Male     Terminal ileum and ascendingcolon       YES      YES   NO    YES   NO    YES
  5                     16              Male      Terminal ileumand sigmoid colon        YES      YES   YES   YES   YES   NO
  6                     14              Male              Terminal ileum                 YES      YES   NO    YES   YES   NO
  7                     19             Female   Terminal ileum and right sidedcolon      NO       YES   YES   YES   YES   YES
  8                     17              Male    Terminal ileum and descendingcolon       YES      YES   YES   YES   NO    NO
  9                     21              Male              Small intestine                NO       YES   YES   YES   NO    NO
  10                    20              Male    Terminal ileum and right sidedcolon      YES      YES   YES   YES   YES   YES
  11                    24             Female             Terminal ileum                 NO       YES   NO    NO    YES   NO
  12                    21              Male              Terminal ileum                 YES      YES   YES   YES   YES   NO
  13                    22             Female     Terminal ileumand sigmoid colon        YES      YES   YES   YES   YES   NO
  14                    23              Male    Terminal ileum and right sidedcolon      NO       YES   YES   YES   YES   NO
  15                    23              Male              Small intestine                NO       YES   YES   YES   YES   NO
  16                    17              Male    Terminal ileum and right sidedcolon      NO       YES   YES   YES   YES   NO
  17                    13             Female    Terminal ileum and ascendingcolon       YES      YES   YES   YES   YES   YES
  18                    24             Female             Terminal ileum                 NO       YES   YES   YES   YES   NO
  19                    25              Male     Terminal ileum and ascendingcolon       NO       YES   YES   YES   YES   YES
  20                    11              Male    Terminal ileum and right sidedcolon      YES      YES   YES   YES   YES   YES
  21                    21             Female    Terminal ileum and ascendingcolon       YES      YES   YES   YES   NO    NO
  22                    14             Female   Terminal ileum and right sidedcolon      NO       YES   YES   YES   NO    YES
  23                    11              Male    Terminal ileum and right sidedcolon      YES      YES   YES   YES   YES   YES
  24                    26              Male              Terminal ileum                 NO       YES   YES   YES   NO    YES
  25                    29              Male              Terminal ileum                 NO       YES   YES   YES   YES   YES

TB: tuberculosis.

DNA Extraction {#s2b}
--------------

Genomic DNA was extracted from EDTA-anticoagulated peripheral venous blood samples using a QIAamp DNA Blood Midi Kit (Qiagen, Germany) according to the manufacturer's instructions.

Whole Exome Sequencing and Variant Detection {#s2c}
--------------------------------------------

Using an E210 ultrasonicator (Covaris, MA, USA), the genomic DNA samples were randomly fragmented into 250--300 bp fragments and subjected to library preparation according to NimbleGen's standard protocol. Target region enrichment was performed for the shotgun libraries using the NimbleGen SeqCap EZ custom design kit (NimbleGen, Madison, WI, USA), which consisted of SeqCap EZ Human Exome Library v2.0 and a continuous region covering the MHC genes. The enriched shotgun libraries were sequenced using the Hiseq2000 platform, and 90-bp paired-end reads were generated. Raw image data and base calling were processed by Illumina Pipeline software version 1.7 with the default parameters. Quality control for the reads was performed by discarding adaptor-containing reads and low-quality reads. For SNP calling, SOAP aligner [@pone.0099807-Li1] was used to align the reads to the human reference genome (hg19), and SOAP snp [@pone.0099807-Li2] was then used to assemble the consensus sequence and call SNPs. As another quality control, low-quality SNPs satisfying one of the four following criteria were discarded: (i) genotype quality\<20; (ii) total reads covering the variant site\<4; (iii) estimated copy number \>2; (iv) distance from the nearest SNP\<5 bp (except for SNPs present in dbSNP). For indel calling, high-quality reads were aligned to the human reference genome using BWA (version 0.5.9-r16) [@pone.0099807-Li3]. GATK Indel Realigner was used to realign reads around insertion/deletion sites, and then small indels were called using the IndelGenotyperV2 tool from GATK (version v1.0.4705) [@pone.0099807-McKenna1], [@pone.0099807-Wang1]. Indels were called as heterozygous and homozygous if indel-supporting reads consisted of 30--70% and \>70% of the total reads, respectively. SNP and indel detection was performed only for the targeted regions and flanking regions within 200 bp of the targeted regions.

Variant Annotation and Prioritization {#s2d}
-------------------------------------

The detected variants were annotated based on four databases, including NCBI CCDS, RefSeq, Ensembl and Encode (<http://genome.ucsc.edu/ENCODE/>). Exclusion steps were taken to help identify candidate mutations. Variants falling within intergenic, intronic and untranslated regions and synonymous substitutions were excluded; variants documented in 4 public genetic variant databases, including dbSNP132, 1000 Genomes, HapMap and YH (<http://yh.genomics.org.cn/>), with an allele frequency \>0.5% (except for YH) were rejected; and variants shared by 2 exome sequenced cases and absent from 2 exome sequenced controls were kept. Additionally, we used the following criteria to evaluate and prioritize the candidate genes: (i) SIFT (<http://sift.bii.a-star.edu.sg/>), MutationTaster (<http://www.mutationtaster.org/>), PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/index.shtml>) and PMut (<http://mmb.pcb.ub.es/PMut/>) were used to predict whether single amino acid changes in genes would alter the protein function; (ii) the conservation of candidate mutations was analyzed by evaluating the GERP score (<http://snp.gs.washington.edu/SeattleSeqAnnotation137/>); (iii) the candidate mutations' total frequency of occurrence in the EVS (<http://evs.gs.washington.edu/EVS/>) and the BGI in-house database was analyzed and (iiii) the tissue distributions and functions were analyzed using the online tools BioGPS (<http://biogps.org/>), Entrez Gene (<http://www.ncbi.nlm.nih.gov/gene>) and Proteinatlas (<http://www.proteinatlas.org/>).

As a final step, we compared and prioritized the remaining candidate genes using 4 internet tools: GeneDistiller2 (<http://www.genedistiller.org/>), SUSPECTS (<http://www.genetics.med.ed.ac.uk/suspects/index.shtml>), ToppGene (<http://toppgene.cchmc.org/>) and Endeavour (<http://www.esat.kuleuven.be/endeavour>). To prioritize the SNVs and genes, we chose 20 reported CD susceptibility genes (*NOD2*, *ATG16L1*, *STAT3*, *IL23R*, *IL10R2*, *IL10R1*, *JAK2*, *ICOSLG*, *CDKAL1*, *MST1*, *PTGER4*, *IRGM*, *TNFSF15*, *ZNF365*, *NKX2-3*, *PTPN2*, *PTPN22*, *IL12B*, *XIAP* and *ITLN1*) as the training set.

Validation Phase {#s2e}
----------------

All shared SNVs of the two affected individuals were verified for all members acquired from family A to detect co-segregation, by direct polymerase chain reaction (PCR) amplification followed by Sanger sequencing (PCR primers are listed in [Table 3](#pone-0099807-t003){ref-type="table"}, Invitrogen). The sequencing reactions were conducted on an ABI 3730XL DNA Analyzer.

10.1371/journal.pone.0099807.t003

###### The PCR primers of 22 candidate SNPs by Sanger Sequencing.

![](pone.0099807.t003){#pone-0099807-t003-3}

  SNP_ID               Gene      F-primer sequences (5′-3′)    R-primer sequences (5′-3′)
  ----------------- ----------- ----------------------------- ----------------------------
  chr17_55183450      *AKAP1*        TCAGAGTCCTCGGGCATT           CTGCTACATACTCTTCCTCC
  chr20_30232655     *COX4I2*        ACAGTCCTTGGGGTCTAA           CCACTGCTTCTTCTCATAG
  chr9_110249480      *KLF4*         AGTCCCGCCGCTCCATTA            TCTTTGGCTTGGGCTCCT
  chr1_26368197      *SLC30A2*      ACTGCCTTATTCTGAACTGT           GAAGCATAATCCTCACCC
  chr7_73279329      *WBSCR28*        GAGAATCGCCCGAAACC            CCAGGCACTGAGCAAGG
  chr9_125582872      *PDCL*         GATTCTTGTTGTGCCTCAG          TTCCTGGTGAACTGACTGC
  chr6_90418252       *MDN1*          AACCTCTTCCCCATCAT            TCCAACACCCCACAACT
  chr20_420894       *TBC1D20*       GACCTGACACCTGCCTTTC           ACCCAGCATTTCCCAACT
  chr9_2717768        *KCNV2*         CCACAGCCAGGAGGAAA            CTCGTAGTCGTCGCACA
  chr16_20492206     *ACSM2A*         CAGGGCAGGGGATTTAG          TTGCTGGATCGTATGGTAGTT
  chr15_41275952      *INO80*        AGCCAAAGCAGCCTCAAC            GGAATCAGGACCTTACCC
  chr6_168366533      *MLLT4*        GAAGCAGGAGGCTGAGAA            TTGAGGTAGGAGGCGTTT
  chr3_196921405      *DLG1*     GGTAAGAAATGAGCAATCAATATTCAG    GGGCGAACCTACATGAAAGAATA
  chr1_1470881       *TMEM240*     GACGCCTCCGAGAACTACTTTG         ACAGCTTGGGCAGCCAGGTC
  chr16_16170185      *ABCC1*         AACCCGTGGCTGATGTC            TGTCCAAGGCTGCTGTA
  chr15_39885853      *THBS1*         TGGGTGCTGAGGATGTC            TGGTGATGCTGGGAACT
  chr10_116225553    *ABLIM1*         TTCCTTGGCAGTGTTTG           GGAAATGTTTAGTCGTTGA
  chr7_98602860       *TRRAP*         TTTCCCGTGACAGTTCG            CTCTTGGTGGTCTCCTTT
  chr6_152536152      *SYNE1*         TTGGCTTTTCGCTATTC            ACCTTGACTGCGGACTT
  chr14_21860964      *CHD8*         GCCCAAGGTAACAAACAG            CCAGGAGTCAATGAGGGA
  chr7_99160120      *ZNF655*        TATGGGCTTTATTCCGTAG           CGGAGAAGACGATGTGAA
  chr7_87051466       *ABCB4*         ATCCAAGTGGGCGTTTT            TGAATGTCTGCTGAGGG

Genotyping was conducted by the MassARRAY (MALDI-TOF MS) method using the SEQUENOM System (Sequenom, Inc.) to screen the candidate genes in an additional 401 HC individuals (278 sporadic CD patients and 123 UC cases), and the data were analyzed using TYPER 4.0 software. The primer sequences for genotyping were designed and synthesized using Primer 5.0 software (PCR primer sequences are listed in [Table 4](#pone-0099807-t004){ref-type="table"}, and the primers were synthesized by Invitrogen). To further study the genes (*DLG1* and *PDCL*) that we identified through the series of steps listed above, we applied PCR amplification followed by Sanger sequencing to examine all of the exons of *DLG1* and *PDCL* in 25 young and intractable CD cases (the PCR primer sequences are listed in [Table 5](#pone-0099807-t005){ref-type="table"}).

10.1371/journal.pone.0099807.t004

###### The primers of the 22 candidate SNPs for the MassARRAY method.

![](pone.0099807.t004){#pone-0099807-t004-4}

  SNP_ID               Gene        F-primer sequences (5′-3′)        R-primer sequences (5′-3′)
  ----------------- ----------- --------------------------------- --------------------------------
  chr17_55183450      *AKAP1*    ACGTTGGATGAGAGGGCAAGAGAGACAGGT    ACGTTGGATGACAGAGCTTCTTCAAGCACC
  chr20_30232655     *COX4I2*    ACGTTGGATGAGCGCATGCTGGACATGAAG    ACGTTGGATGCTGCTTCTTCTCATAGTCCC
  chr9_110249480      *KLF4*     ACGTTGGATGTCTTTGGCTTGGGCTCCTCT     ACGTTGGATGATGATGCTCACCCCACCT
  chr1_26368197      *SLC30A2*   ACGTTGGATGAACCTTGACCATCCTGAGAG    ACGTTGGATGAAGAGCAAAAAGGGAGCCAC
  chr7_73279329      *WBSCR28*   ACGTTGGATGTGATGGCTGACGGTTGTCTC    ACGTTGGATGGGAGCAGGAAATTATAGAGG
  chr9_125582872      *PDCL*     ACGTTGGATGTGACTCTGAAGGAGTTTGCC    ACGTTGGATGATTCGCTGCTTCCGGTACTG
  chr6_90418252       *MDN1*     ACGTTGGATGTTTGATGGACTTTGACCCAC    ACGTTGGATGTGCAGCTGATTCTAAAAGGG
  chr20_420894       *TBC1D20*   ACGTTGGATGATGGGTGATGGTGAACCCAG    ACGTTGGATGACCCACTGATGCCGATTTAC
  chr9_2717768        *KCNV2*    ACGTTGGATGAGCCATGCTCAAACAGAGTG    ACGTTGGATGCCTCATTCTCCGTCGTGTTC
  chr16_20492206     *ACSM2A*    ACGTTGGATGGGTAGAGAATGCACTGATGG    ACGTTGGATGACGGGGTCTGGGCTGCTGAT
  chr15_41275952      *INO80*    ACGTTGGATGACAACCAAACCAGTGCTGGG    ACGTTGGATGGTCTCAGATACCGTGAATGG
  chr6_168366533      *MLLT4*     ACGTTGGATGAGACAGCACGACGAGGCGG    ACGTTGGATGTAGTCCCGGGGAAGCGGAG
  chr3_196921405      *DLG1*     ACGTTGGATGGAACCAATTCTGGACCTATC    ACGTTGGATGGGATGAAGATACACCTCCTC
  chr1_1470881       *TMEM240*   ACGTTGGATGAGCCGCCTGACCGCCCCTGT    ACGTTGGATGTGCACAGCTTGGGCAGCCAG
  chr16_16170185      *ABCC1*    ACGTTGGATGTGTCCCTGACATGTCTCTGT    ACGTTGGATGTGAATGTGGCATTCCTCACG
  chr15_39885853      *THBS1*     ACGTTGGATGTGGCGAGCACCTGCGGAAC    ACGTTGGATGTCCAGGGCTTTGCTTCTTAC
  chr10_116225553    *ABLIM1*    ACGTTGGATGTGTACACAGGGGAGTTGATG    ACGTTGGATGAGGATGTTCGGGATCGGATG
  chr7_98602860       *TRRAP*     ACGTTGGATGTGCAACACACGCTCCTCTC    ACGTTGGATGTGGCAAGATCTACCCATACC
  chr6_152536152      *SYNE1*    ACGTTGGATGCTTCCTTCTAGGGACAGATG    ACGTTGGATGGGTAACCTATATCCAAGCTC
  chr14_21860964      *CHD8*     ACGTTGGATGCACAGCTAGTACTCAGACTC    ACGTTGGATGCGAGGTCAATACGGTTTATC
  chr7_99160120      *ZNF655*     ACGTTGGATGGATAAACCGAATAATAAGG    ACGTTGGATGACCTCTACAGAGAAGTGATG
  chr7_87051466       *ABCB4*    ACGTTGGATGGCAGAAGTGCAACATATTCTC   ACGTTGGATGACCTACCTGAAGGAAGAAAG

10.1371/journal.pone.0099807.t005

###### The PCR primers of all exons of *DLG1* and *PDCL.*
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  Primer ID      F-primer sequences (5′-3′)     R-primer sequences (5′-3′)    Annealing temperature (°C)
  ------------ ------------------------------- ----------------------------- ----------------------------
  ***DLG1***                                                                 
  Exon 1             CCGACTTCTGTCTGTTCTT             GGACCGTGCTGTCTCAT                    54
  Exon 2             CTCCTCCGTTTTCTAATG              GTTACCGAATGCCTCAG                   51.5
  Exon 3         GTTAAGTAGTTTGCCTGAACTTGTAGC      CAGATGAAGCCTTGTTGAGGTCT                 62
  Exon 4         GGTAAGAAATGAGCAATCAATATTCAG      GGGCGAACCTACATGAAAGAATA                55.5
  Exon 5             TTTATCTTTATGGCACAGC            AAATGGCAAATCCTGACT                   51.5
  Exon 6             TTCTGTTTGGTGCTGGAG             GGTCTTCGCATTTGTATC                   55.5
  Exon 7            CAGAGAAGGATCGGAGGTTGA        GTAAATGGAAACTCTTGGGACTATC               58.8
  Exon 8              CCTCCAGAACAAGTCCA            GTATTTATCCCTTATCCAGTC                 51.5
  Exon 9            TGTTCCTTTTGCTGGCCCTT           ATGACTGCACCACTGGACTC                   63
  Exon 10          TTCGTAACTCTAGGAGCAGCTGT         CTGTGCATACAAGCCCTCAAC                  61
  Exon 11            AGACTGGGAGAATAGGAGG            TCACTAATGGCATCACAAC                  55.5
  Exon 12          TTGAGACTAACCTGGGCAACAT        AAGGACAATTTACCAAGCCTCAA C                61
  Exon 13            CTTCTAAGTAGGGGCAGTG           AATAGGTCCAGTGAAAATAAC                  54
  Exon 14           CAGTAGGCGTGAGAATGTGGC          GCCTGGGCAGTAAGAGTGGA                   63
  Exon 15            GATTACTGCTGTCTGATGC            GCCTCCTTTGCTACTATG                   55.5
  Exon 16       TCAATATAACTTACCATTGGATTACAATC   AGTACTATTACCTGTAGTTGCCATGCT               57
  Exon 17          TTAAACTCAGAAATGGTGCCTCA         GGTCTGTGAAATGGGTGCTTG                  61
  Exon 18        AGGTATAAATGAACTATGCTGTCTGAA      CCTTGAAGACAATTAGCAACCTG                58.8
  Exon 19             AGTTTGTCCCCTTTGCC              TCAGAATCCCTCCACCC                   55.5
  Exon 20          AAATAAAGGAGTAGCACATAGC          GAAAGAAGTGGGATAAACAG                   54
  Exon 21         CATCTTTGGTTGATGGTAGAGTGAG      AGAAAGGACAATAATATGGAGGATG               58.8
  Exon 22         ATCCATCCTCCATATTATTGTCCT          ACCCGGCCCTTATCTCCT                    57
  Exon 23        TTTCATTTCCTATCTAAAGTTTGCTG       ATGGTTCTGCCTCACATTCTGT                  57
  Exon 24           TGTGTCATCTCTCCTTTGCCA          GAGCCGAGTCATACCATTGC                   62
  Exon 25          CTATGGGATTGTACCCAGTTTCC         GGTCAGGCCATTCCATCTTC                   57
  ***PDCL***                                                                 
  Exon 1          TGTCCTGGAAATTGTAGGATCTCA       GACTAGGTTACCTCTGAAAGTGGGA               60.5
  Exon 2            ATGTTGGGCATTAGCTTGGC         TTTGACAGGGCTCTATGATTTCTC                60.5
  Exon 3-1           TCAAGTGATCCGCTCGTCT            AGCTTCAAGGTCCACAGCA                  60.5
  Exon 3-2          GCCAGCAGTCAGTTCACCAG         TTTGACAGGGCTCTATGATTTCTC                60.5

SPSS17.0 statistical software was used for statistical analysis, the measurement data were expressed as means +/− standard deviation (SD). PLINK was performed on analysis of genotype data. P values\<0.05 were considered as significant.

Results {#s3}
=======

Whole Exome Sequencing of the CD Family {#s3a}
---------------------------------------

Whole exome sequencing was performed on DNA extracted from the peripheral blood of 4 members of Family A using next-generation sequencing technology. As shown in [Table 6](#pone-0099807-t006){ref-type="table"}, we obtained at least 88.5 million reads that mapped to the target region for each exome, more than 98.5% of the target region was covered and the mean depth of the target region was 128.64×, 148.90×, 202.26× and 158.25×. The summary statistics of the total quality-passing SNPs and indels are all listed in [Table 6](#pone-0099807-t006){ref-type="table"}.

10.1371/journal.pone.0099807.t006

###### Summary of original exome sequencing data of four familial individuals.
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  Exome Capture Statistics              Daughter     Father     Grandmother    Mother
  ------------------------------------ ----------- ----------- ------------- -----------
  Target region (bp)                    48959543    49062223     48959543     48959543
  Raw reads                             243896508   204592452    253503938    192147514
  Raw data yield (Mb)                     21951       18413        22815        17293
  Reads mapped to genome                204193470   145810600    202993882    156292035
  Reads mapped to target region^(2)^    88581652    101995817    138982919    108872112
  Data mapped to target region (Mb)      6298.25     7305.56      9902.46      7748.06
  Mean depth of target region (X)        128.64      148.90       202.26       158.25
  Coverage of target region (%)           98.77       98.56        98.81        98.75
  Average read length (bp)                89.87       89.84        89.78        89.85
  Total quality-passing SNPs             116950      114204       119780       117371
  Total quality-passing indels            7442        7361         7773         7500

Bioinformatic Analysis Identifies 22 Candidate Genes {#s3b}
----------------------------------------------------

In total, 82 variants shared by the 2 cases remained through the exclusion of 4 public genetic databases (the procedures are shown in [Table 7](#pone-0099807-t007){ref-type="table"}), and no reported IBD single nucleotide variant was found. After performing filtering steps for gene function and mutation prediction, we obtained 22 candidate genes ([Table 8](#pone-0099807-t008){ref-type="table"}). Using 4 internet tools, we acquired the top 6 genes from the 22 candidates: *THBS1*, *KLF4*, *SYNE1*, *CHD8*, *PDCL* and *DLG1*. These genes were the most likely to be the genetic cause of the 2 affected patients.

10.1371/journal.pone.0099807.t007

###### Filtration of SNPs/Indels.
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  Individual ID                                                                                                                   Grandmother     Mother       Daughter       Father
  ------------------------------------------------------------------------------------------------------------------------------ ------------- ------------- ------------- -------------
  Total SNPs and indels                                                                                                           173991+7773   172848+7500   172005+7442   173055+7361
  Quality-passing SNPs and indels                                                                                                 119780+7773   117371+7500   116950+7442   114204+7361
  Protein-disrupting SNPs and indels (PDSI)                                                                                       14553+1369    14345+1314    14581+1280    14547+1294
  PDSI after filtering against dbSNP                                                                                               2144+382      2138+366      2108+348      2129+359
  PDSI after filtering against dbSNP+1000 Genomes                                                                                  1459+220      1498+221      1469+189      1448+208
  PDSI after filtering against dbSNP+1000 Genomes+HapMap                                                                           1457+220      1497+221      1467+189      1446+208
  PDSI after filtering against dbSNP+1000 Genomes+HapMap+YH                                                                        1420+220      1460+221      1438+189      1413+208
  PDSI after filtering against dbSNP+1000 Genomes+HapMap+YH+inhouse dataand fitting a dominant model **(shared by two cases)**         0             0           82+0      
  Filtered candidate genes                                                                                                                                      **22**     
  Sanger sequence for validation                                                                                                                                **22**     

10.1371/journal.pone.0099807.t008

###### List of 22 candidate genes and mutations prediction.
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  NO    Chromosome   Position    Reference   Gene name      Codons      SIFT Prediction   MutationTaster Prediction   ConsScore GERP
  ---- ------------ ----------- ----------- ------------ ------------- ----------------- --------------------------- ----------------
  1        chr6      90418252        C         *MDN1*     GAC7861CAC       DAMAGING             polymorphism               2.23
  2       chr14      21860964        C         *CHD8*     CGT5636CAT       DAMAGING            disease causing             5.34
  3        chr9      125582872       T         *PDCL*      GAT398GGT       DAMAGING            disease causing             5.47
  4       chr17      55183450        G        *AKAP1*      GTG625ATG       DAMAGING             polymorphism               4.22
  5       chr15      39885853        G        *THBS1*     GGA3251GAA       DAMAGING            disease causing             5.78
  6       chr16      16170185        G        *ABCC1*     GGG1915TGG       DAMAGING            disease causing             4.11
  7        chr1       1470881        G       *TMEM240*     TCG380TTG       DAMAGING            disease causing             3.37
  8        chr7      73279329        C       *WBSCR28*     CAG79AAG        DAMAGING             polymorphism               4.43
  9        chr9       2717768        C        *KCNV2*      TCC29TGC        DAMAGING            disease causing             4.45
  10       chr7      99160120        A        *ZNF655*        --              --                     --                    3.92
  11      chr15      41275952        G        *INO80*         --              --                     --                    2.69
  12      chr10      116225553       G        *ABLIM1*    CGG1345TGG       DAMAGING            disease causing             3.37
  13       chr1      26368197        T       *SLC30A2*     ATG685GTG       DAMAGING            disease causing             5.6
  14      chr20      30232655        T        *COX4I2*     GTG464GCG       DAMAGING            disease causing             4.38
  15       chr6      167570520       G        *GPR31*      ACG800ATG       DAMAGING             polymorphism               2.65
  16       chr6      168366533       G        *MLLT4*     GGA4993AGA       DAMAGING            disease causing             5.03
  27      chr16      20492206        C        *ACSM2A*    ACG1472ATG       DAMAGING             polymorphism               3.26
  18      chr20       420894         C       *TBC1D20*     GTG766ATG       DAMAGING            disease causing             5.65
  19       chr9      110249480       G         *KLF4*         --              --                     --                    3.45
  20       chr3      196921405       A       ***DLG1***    ATC374ACC       TOLERATED           disease causing             5.17
  21       chr6      152536152       C        *SYNE1*     CGT22022CAT      TOLERATED           disease causing             5.07
  22       chr7      87051466        T         *ABCB*     ATT2287GTT       TOLERATED            polymorphism               4.85

Sanger Sequencing and Genotyping Combined with Bioinformatic Analyses Identifies DLG1 as a Potential Susceptibility Gene {#s3c}
------------------------------------------------------------------------------------------------------------------------

Sanger sequencing confirmed the presence of the 22 mutations in the affected father and daughter. 10 healthy members of family A were sequenced to test for these variants. We found that one family member carried the variant in the *KLF4* gene. The other 21 mutations absent in healthy family members showed co-segregation.

The genotyping of the 22 SNVs indicated that 8 variants in *THBS1*, *SYNE1*, *CHD8*, *TMEM240*, *AKAP1*, *COX4I2*, *ZNF655* and *KCNV2* were positive in 401 HC, whereas the other 14 variants were negative. We again focused on the 6 top candidate genes (*THBS1*, *KLF4*, *SYNE1*, *CHD8*, *PDCL* and *DLG1*) identified through the prioritization analysis. In contrast to *THBS1*, *KLF4*, *SYNE1* and *CHD8*, none of the 401 HC was found to carry *PDCL* or *DLG1* mutations. Subsequent genotyping of 22 SNVs in 401 sporadic IBD cases indicated that one female CD patient aged 21 years carried a mutation in *DLG1* ([Table 9](#pone-0099807-t009){ref-type="table"}), and no patients had variation in *PDCL*. A PLINK analysis showed the variant in *DLG1*was of significance (*P*\<0.05).

10.1371/journal.pone.0099807.t009

###### Distributions of rare variants in the *DLG1* gene.
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  Patient ID             Gender   Age (years)   Nucleotidechange   Amino acidchange   ChromosomePosition   Exon     Sequencing method
  --------------------- -------- ------------- ------------------ ------------------ -------------------- ------ -----------------------
  **CD Family A**                                                                                                
  Father(diagnosed)       Male        44           c.374T\>C           p.I125T          chr3_196921405      4             Exome
  Daughter(diagnosed)    Female       16           c.374T\>C           p.I125T          chr3_196921405      4             Exome
  Mother(unaffected)     Female       42               --                 --                  --            --            Exome
  Grandma(unaffected)    Female       81               --                 --                  --            --            Exome
  **CD Family B**                                                                                                
  Case 1(diagnosed)       Male        39           c.833G\>A           p.R278Q          chr3_196865242      9     Direct PCR sequencing
  Case 2(diagnosed)       Male        42           c.833G\>A           p.R278Q          chr3_196865242      9     Direct PCR sequencing
  Case 3(diagnosed)      Female       32           c.833G\>A           p.R278Q          chr3_196865242      9     Direct PCR sequencing
  Case 4(diagnosed)      Female       24           c.833G\>A           p.R278Q          chr3_196865242      9     Direct PCR sequencing
  CJ 5(undiagnosed)      Female       56           c.833G\>A           p.R278Q          chr3_196865242      9     Direct PCR sequencing
  CJ 6(undiagnosed)      Female        6           c.833G\>A           p.R278Q          chr3_196865242      9     Direct PCR sequencing
  CJ 7(undiagnosed)      Female        6           c.833G\>A           p.R278Q          chr3_196865242      9     Direct PCR sequencing
  CJ 8(undiagnosed))      Male         7           c.833G\>A           p.R278Q          chr3_196865242      9     Direct PCR sequencing

By examining all of the exons of *PDCL* and *DLG1* in 25 young and intractable CD patients, we found two cases ([Table 2](#pone-0099807-t002){ref-type="table"}, Patient ID are 3 and 4) who carried another variant in *DLG1* ([Figure 2](#pone-0099807-g002){ref-type="fig"}, exon 9, c.833G\>A, p.R278Q). We traced Patient 3, 4 and their families, and found that two cousin sisters (Cases CJ2 and CJ3) and one brother (Case CJ4) of Patient 4 who were unexpectedly found to have ulcers in the terminal ileum by endoscopy, and a biopsy showed non-specific chronic inflammation. After being treated with 5-ASA and azathioprine, four affected cases in this family have almost achieved their colonic mucosal healing. Cases CJ2, CJ3 and CJ4 were all found to be carriers of mutation R278Q (c.833G\>A) by Sanger sequencing, and the family was called family B. We found 4 unaffected carriers (CJ5, CJ6, CJ7 and CJ8) of this variant after sequencing the other 15 members of family B, and these individuals will be followed up. CJ5 received a diagnosis of rheumatic heart disease with arthritis. The variants and carriers of *DLG1* are listed in [Table 9](#pone-0099807-t009){ref-type="table"}. Neither of the monozygotic CD twins carried any mutation in all 3 exons of *PDCL* or in all 25 exons of *DLG1*.

![Chromatogram of *DLG1* gene mutations.\
The Sanger sequence traces from normal human controls are shown in panel A and B; the mutations were heterozygous at the corresponding locus (orange arrows indicating) in panel C and D.](pone.0099807.g002){#pone-0099807-g002}

Bioinformatics analyses were used to dissect the two non-synonymous mutations of *DLG1* found in the study described above. MutationTaster showed that the variant in *DLG1* ([Figure 2](#pone-0099807-g002){ref-type="fig"}, c.374T\>C, p.I125T) was likely to be disease-causing. We compared the SNV sequence of species at different evolutionary distances by GERP and found that the amino acid substitution of *DLG1* was highly conserved. Regarding another variant of *DLG1* ([Figure 2](#pone-0099807-g002){ref-type="fig"}, exon 9, c.833G\>A, p.R278Q), the PMut analysis of the mutation indicated that it is pathological (<http://mmb.pcb.ub.es/PMut/>), and the prediction from PolyPhen-2 was that the mutation was most likely damaging; however, the MutationTaster analysis indicated polymorphism, and SIFT predicted the mutation to be tolerated.

Discussion {#s4}
==========

Rare and low-frequency variants might have substantial effect sizes in complex disorders such as IBD [@pone.0099807-Cho1]. A main goal of human genetic studies is to identify uncommon variants that play important roles in pathogenesis and reveal the familial transmission of diseases [@pone.0099807-Teer1], [@pone.0099807-Nazarian1]. Furthermore, uncommon alleles shared by affected individuals in a family are more prone to familial clustering of disease than common alleles carried in a population.

In this study, we applied whole exome sequencing to anatomize the genetic background of a Chinese family with CD and successfully identified genetic variants in the coding regions of the *DLG1* gene that may be associated with increased risk of CD. We first identified a novel SNV c.374T\>C (p.I125T) in exon 4 of *DLG1* through whole exome sequencing and bioinformatic analysis. In subsequent validation studies, we also identified 4 CD patients of another Han Chinese family harbored the variant c.833G\>A. Altogether these data suggest that *DLG1* is a susceptible gene for CD.

*DLG1* encodes a multi-domain scaffolding protein, which may have a role in septate junction formation, signal transduction, cell proliferation, synaptogenesis and lymphocyte activation (<http://www.ncbi.nlm.nih.gov/gene/>). The DLG1 protein is composed of an N-terminal L27b oligomerization domain, a proline-rich domain (PRD), three PDZ (PSD-95, Dlg and ZO-1) domains, an SH3 (Src Homology 3) domain and a catalytically inactive GUK (GUanylate Kinase) domain. During antigen recognition, these modular domains allow DLG1 to co-localize with synaptic actin, translocate into sphingolipid-rich microdomains within the IS and associate with Lck, ZAP-70, Vav, WASp Ezrin and p38 [@pone.0099807-ONeill1]. *DLG1* has been shown to play roles in T cell polarity and T cell receptor signal specificity [@pone.0099807-Humphries1], [@pone.0099807-Xavier1], and be involved in the generation of memory T cells [@pone.0099807-Gmyrek1]. The loss of *DLG1* leads to increased invasion in response to pro-tumorigenic cytokines, such as IL-6 and TNF-α [@pone.0099807-Chatterjee1], [@pone.0099807-Surena1].

In accord with the suggested autoimmune nature of CD, strong evidence has implicated T cells and T-cell migration to the gut in initiating and perpetuating the intestinal inflammatory process and tissue destruction [@pone.0099807-Strober1], [@pone.0099807-MacDonald1]. Anti-cytokine agents are therefore likely to be useful in the treatment of IBD [@pone.0099807-Plevy1], [@pone.0099807-Danese1]. After intravenous injection with six cycles of infliximab, the affected daughter in Family A has almost achieved mucosal healing of her colonic disease and was likely to have a better prognosis than those *DLG1* mutation carriers who did not accept infliximab treatments in our study. It was corroborative evidence that *DLG1* was causative for the CD patients of the two Chinese families.

Complex human disease is a large collection of individually rare, even private variants [@pone.0099807-McClellan1]. A single locus can harbor both common variants of weak effect and rare variants of strong effect [@pone.0099807-Altshuler1]. The results of our study of two CD families indicated genetic heterogeneity and susceptibility. We analyzed family A using an autosomal dominant model, and several factors were important to the success of this study.

First, according to the database at our center [@pone.0099807-Zhao1], although the incidence of CD and UC is still low, the number of cases and severity of disease are increasing in China [@pone.0099807-Ng1], [@pone.0099807-Yi1], which provides the appropriate conditions to recruit patients for the subsequent validations.

Second, a stepwise approach was taken to help narrow down the list of genetic variants responsible for this disease. For the genetic susceptibility of CD, despite the success of GWAS in identifying significantly associated loci [@pone.0099807-Franke1], the currently identified variants are estimated to account for less than a quarter of the predicted heritability [@pone.0099807-Clarke1]. Uncommon alleles may be maintained at a lower frequency in the population through negative selection, and it is not possible to create a complete catalog in the general population [@pone.0099807-Gibson1]. Therefore, rare causal variants are not likely to be found in public SNP databases and control exomes [@pone.0099807-Tennessen1]. We did not find mutations in any reported susceptibility genes that were shared by the affected father and daughter, which suggested that other variants may be associated with CD in these 2 individuals. To predict the impact of nonsynonymous variants, we applied 4 popular methods (PolyPhen2, SIFT, MutationTaster and PMut) [@pone.0099807-Ng2], [@pone.0099807-Schwarz1]. However, none of these methods was perfectly sensitive or specific. Regarding the mutation c.374T\>C, SIFT and MutationTaster predicted it to be tolerated and disease causing, respectively. Different prediction algorithms used different information, and each had its own relative merits. It is thought to be better to use predictions from multiple algorithms rather than relying on a single one [@pone.0099807-Liu1], [@pone.0099807-Brunham1]. We also used several different bioinformatic methods to filter and prioritize the SNVs and genes to increase the robustness of the analysis results.

Finally, to confirm the results and identify the susceptibility gene, we used genotyping and Sanger sequencing methods for validation. Traditional Sanger sequencing is the gold standard for mutation detection [@pone.0099807-Gilissen1]. We were able to narrow the scope to only a few genes through these steps. By scanning all exons of *DLG1* and *PDCL*, a nonsynonymous variant c.833G\>A of *DLG1* was found in family B, thus confirming that *DLG1* is a gene whose mutation is associated with high risk.

Some limitations must be addressed. First, IBD patients with family history are rare among Han Chinese. In this family study, there were only two affected members, so the size of the pedigree was small. Second, the patients studied did not have an onset as early as those were previous reported in Caucasian population [@pone.0099807-Glocker1], [@pone.0099807-Glocker2]. Third, because of genetic heterogeneity, the variants appear to be present only in a subset of CD patients, and were not carried by the pair of monozygotic twins studied. Furthermore, in complex diseases, a central problem is that each variant only makes a small contribution to the disorder [@pone.0099807-Kevin1]. Other candidate genes discovered by us, such as *THBS1*, *KLF4*, *SYNE1*, *CHD8* and *PDCL*, may also contribute to CD. However, variation in these genes must be identified in more cases and controls. Additionally, considering that the variant was also present in the unaffected individuals of family B, other disease-causing factors lying outside of our set of candidate genes may also exist [@pone.0099807-Gibson2]. Finally, functional analyses are needed to elucidate the biological role of this gene in CD susceptibility.

In conclusion, we report the discovery of coding region variants in *DLG1* in human CD through whole exome sequencing and bioinformatic analysis and identify *DLG1* as a potential susceptibility gene for CD in the Chinese population. Our study also demonstrates that whole exome sequencing is an efficient and cost-effective genetic strategy. Bioinformatic approaches are likely to become useful tools for the discovery of genes and to provide important guidance for finding rare variants in a complex disorder. Finding different, rare and pathogenic mutations in the same gene in unrelated individuals with the same phenotype provides important support for our study. However, confirmation of *DLG1*'s involvement in CD pathogenesis still requires validation in further functional experiments and clinical trials. Personalized medicine is also anticipated to be developed based on definite biological processes and molecular causes.
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